ASH 2013
The American Society of Hematology (ASH) will hold its 55th annual meeting in New Orleans, LA, December 7-10, 2013. The American Journal of Managed Care will be sending daily e-mail blasts with full conference coverage. Sign up on ourregistration page, and check back here during the conference for all of our coverage!
Day 1
In Treating Older CLL Patients, Cost Considerations Are a Factor
New therapies to treat chronic lymphocytic leukemia (CLL) will receive plenty of attention this week at the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. At an education session that opened the meeting Saturday, a physician with the Mayo Clinic made it clear that cost considerations are a reality for many older patients.
Collaboration Between Academia and Pharma to Bring New Therapies to Market More Important Than Ever
With grants from government sources looking less certain, partnerships between academic research center and pharmaceutical companies are more important than ever to keep breakthrough hematology therapies in the pipeline, said Burt Adelman, MD, a hematologist who serves as executive vice president and chief medical officer for Dyax Inc.
Treating the Signs of Multiple Myeloma Before it Starts
Progress in treating multiple myeloma, or cancer of the plasma cells in bone marrow, has advanced significantly over the past decade. Today, questions about the disease often involve finding a treatment that balances the goal of putting a patient into remission especially if stem cell transplantation is a possibility against the toxicity of the treatment itself.
Day 2
Can Genetics Help Unlock the Mysteries Surrounding Adult ALL?
In recent years, overall progress in treating acute lymphoblastic leukemia (ALL), in which malignant white cells multiply in the bone marrow, has been tempered by this fact: Survival rates among children far outstrip those of adults, with childhood rates reaching 85% and adults registering at 45%.
Rituximab, Other Antibodies Offer Hope In Advancing ALL Treatment
Taking aim at relapse rates and overall poor outcomes among adult patients with acute lymphoblastic leukemia (ALL) demands both new therapies and new ways of thinking, according to Anjali S. Advani, MD, of the Cleveland Clinic. Antibodies, which have produced success in treating other blood cancers, offer promise because in some cases the same antigens are involved.
When Less is More: Phase III Results Herald 'Paradigm Shift†in Treating Newly Diagnosed Multiple Myeloma Patients
Treating newly diagnosed patients even older ones with a combination of lenalidomide, marketed by Celgene as Revlimid, and low-dose dexamethasone, a steroid, seems likely to become the new treatment standard for multiple melanoma, based on the presentation of a mass vascular endothelial growth factor inhibitor, ive, multinational Phase III study presented Sunday at the 55th American Society of Hematology Meeting and Exhibition in New Orleans.
Day 3
As Genomics Reveals Diversity of Lymphomas, Questions Arise on Diagnosis, Treatment, and Ethical Issues
Treating lymphoma today starts with an understanding of what is being treated, and the revolution in genetic profiling lets clinicians do that with more precision than ever.
From Laboratory to Licensure: Preclinical Phase Critical in Creating New Targeted Therapies
One billion dollars. That can be the list price for bringing a new cancer-fighting agent from preclinical design through approval by the US Food and Drug Administration, according to Michael R. Grever, MD, of the Ohio State University.
Post-Marketing Research No Longer an Afterthought With Targeted Therapies
With the rise of targeted therapies, the days of letting doctors report informally on unexpected reactions to new cancer drugs are long gone. The change signals a larger role for phase IV, the post-marketing research step in the approval process.